Evidence map›Paper›PMID 42671157›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Longitudinal functional network connectivity changes across the clinical stages of C9orf72 hexanucleotide repeat expansion carriers.

Liwen Zhang, Suvi Häkkinen, Youjin Jung, Maria Luisa Mandelli, Dana Leichter, Chiadi U Onyike, Julio C Rojas, Jolina Lombardi, Maria Luisa Gorno-Tempini, Jennifer S Yokoyama and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Liwen ZhangInstitute for Medical Imaging Technology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Suvi HäkkinenDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Youjin JungDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Maria Luisa MandelliDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Dana LeichterDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Chiadi U OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Julio C RojasDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Jolina LombardiDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Maria Luisa Gorno-TempiniDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Jennifer S YokoyamaDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Virginia E SturmDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Joel KramerDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Brad F BoeveDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Adam L BoxerDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Leah K ForsbergDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Hilary W HeuerDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Eliana Marisa RamosDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Howard J RosenDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Bruce L MillerDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
William W SeeleyDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Taru M FlaganDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Suzee E LeeDepartment of Neurology, Weill Institute for Neurosciences, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
ARTFL/LEFFTDS/ALLFTD Consortia

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
The Alzheimer's Disease Tau Platform Clinical TrialR01AG078457 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L., JOHNSON, KEITH A. · 2023 to 2024
$60.7M
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic InteractionsU19AG079774 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HELENA Chang CHUI, Gyungah Jun · 2023 to 2026
$39.4M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Serggio Carlo Lanata · 2019 to 2026
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal ProteasesU54NS123985 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGARD, DAVID A., KAO, AIMEE · 2021 to 2025
$9.0M
An automated machine learning approach to language changes in Alzheimer’s disease and frontotemporal dementia across Latino and English-speaking populationsR01AG075775 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, Adolfo Martin Garcia · 2023 to 2026
$7.2M
ALLFTD Consortium U19AG063911Alzheimer's AssociationAlzheimer's Drug Discovery FoundationAlzOut and John Douglas French FoundationARTFL & LEFFTDS Consortia U01AG045390ARTFL & LEFFTDS Consortia U54NS092089Association for Frontotemporal DegenerationBluefield Project to Cure Frontotemporal DementiaFrench FoundationGates VenturesGenentechGHR FoundationGlobal Brain Health InstituteJane Tanger Black Fund for Young-Onset DementiasKathrine B. Andersen Endowed ProfessorshipMary Oakley FoundationNancy and Robert Hall Fund for Brain ResearchNCRAD U24AG021886NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG052496NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG058233NIA NIH HHS R01 AG062588NIA NIH HHS R01 AG071756NIA NIH HHS R01 AG073482NIA NIH HHS R01 AG075775NIA NIH HHS R01 AG078457NIA NIH HHS R56 AG075744NIA NIH HHS RF1 AG077557NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG079774NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG057437NIDCD NIH HHS K24 DC015544NIH HHS K24DC015544NIH HHS P01AG019724NIH HHS P30AG062422NIH HHS P30AG062677NIH HHS R01AG038791NIH HHS R01AG052496NIH HHS R01AG057234NIH HHS R01AG058233NIH HHS R01AG062588NIH HHS R01AG071756NIH HHS R01AG073482NIH HHS R01AG075775NIH HHS R01AG078457NIH HHS R56AG075744NIH HHS RF1AG077557NIH HHS RF1NS050915NIH HHS U19AG063911NIH HHS U19AG079774NIH HHS U24AG057437NIH HHS U54NS123985NINDS NIH HHS RF1 NS050915NINDS NIH HHS U54 NS092089NINDS NIH HHS U54 NS123985Päivikki and Sakari Sohlberg FoundationTau Consortium
6 · The paper itself

Abstract

introductionIntrinsic functional connectivity network abnormalities in C9orf72 hexanucleotide repeat expansion carriers emerge during the asymptomatic phase, yet longitudinal studies remain limited. We examined cross-sectional abnormalities and longitudinal connectivity changes across clinical stages.

methodsWe analyzed task-free functional magnetic resonance imaging (fMRI) and structural MRI data in 36 asymptomatic (aSxC9), 17 prodromal (proC9), and 29 symptomatic (SxC9) carriers, and 107 healthy controls (HCs). Functional networks previously found altered in C9orf72, including salience, sensorimotor, default mode, and medial pulvinar thalamic networks, were examined. Associations between longitudinal connectivity and gray matter decline with baseline neurofilament light chain (NfL) concentrations and symptom severity were assessed.

resultsaSxC9 and SxC9 showed longitudinal connectivity changes within specific networks. In aSxC9, connectivity changes correlated with baseline NfL. In proC9 and SxC9, changes in connectivity and gray matter were associated with baseline NfL and symptom severity. DISCUSSION: C9orf72 expansion carriers demonstrate stage-specific network connectivity changes.

Indexed as

BrainC9orf72 ProteinDNA Repeat ExpansionNerve NetAgedCross-Sectional StudiesFemaleGray MatterHeterozygoteHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedProdromal SymptomsC9orf72 ProteinC9orf72 protein, humanasymptomaticC9orf72frontotemporal dementiafunctional connectivitygray matter atrophylongitudinal changesprodromalresting‐state fMRIsymptomatic

Identifiers

PMID42671157
PMCPMC13528451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.